HBIO
Harvard BioscienceBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-22
Current thesis
The constructive case is that Q1 2026 confirmed margin resilience, the refinancing removed the immediate going-concern overhang, and Project Viking can translate into better throughput and lower fixed costs if execution remains orderly.
Posture
Constructive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.3.
What can break
Capital structure risk: $40M of borrowings plus warrant overhang leaves dilution and refinancing sensitivity in place.
Momentum
94
Value
63
Sentiment
27
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $5.00 · Bull $7.25 · Bear $2.75
Data freshness
Prices
As of 2026-07-22
Fundamentals
As of 2026-07-22 • Vendor: Data Vendor v1
Scores
As of 2026-07-22 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-27 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-22
Investment thesis
As of 2026-07-22
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $6.00
Why
Momentum94 · Δ7d -
Value63 · Δ7d -0.3
Sentiment27 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Value · See fundamentals
Momentum
94
26% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
63
39% active weight
Current posture
7d trendFlat
Δ7d
-0.3
Δ21d
-0.3
Sentiment
27
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade B. Momentum 93.7 / Value 63.4 / Sentiment 26.5
Fundamentals (TTM)As of 2026-07-22
Fundamentals (TTM)
As of 2026-07-22
Market Cap
$27.65M
Beta
1.55
Shares Out
4.51M
P/E (TTM) · Derived
-0.5
P/S (TTM)
0.35
P/FCF (TTM)
4.47
Rev YoY
-4.7%
EPS YoY
-93.3%
Gross Margin
+54.1%
Op Margin
-56.1%
Net Debt
$35.66M
Current Ratio
1.99
As of 2026-07-22 • Updated nightlySource: Internal modelMethodology